Controlling Inflammation

targeting acute, life threatening and chronic inflammatory diseases with new and selective inhibitors of the C5a/C5aR signaling pathway of the immune system's complement cascade. 

To learn more about our ongoing phase 3 trial for treating ulcerative pyoderma gangrenosum, please visit

InflaRx Business

Lorem ipsum dolor

InflaRx is developing highly specific therapeutics targeting the C5a/C5aR signaling axis of the complement systemInflaRx has made breakthrough discoveries in the area of selective anti-C5a antibody generation and C5a receptor (C5aR) inhibitors.

read more ...

Clinical Programs

InflaRx focuses on diseases with high unmet medical need. Vilobelimab, the company's first-in-class anti-human C5a monoclonal antibody is currently being developed in several chronic inflammatory diseases, as well as oncology and for the treatment of critically ill COVID-19 patients.  

read more ...



Gohibic (vilobelimab) - FDA has issued an emergency use authorization (EUA) to treat certain critically ill COVID-19 patients.

read more


Stock Price

NASDAQ: IFRX $1.64 0 (0%) Volume 50496 Pricing delayed by 20 minutes

The latest information on InflaRx share price with interactive charts, comparative analysis, historic figures and latest trade price is available here.